188 related articles for article (PubMed ID: 27581662)
1. Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy.
Ziogas DE; Spiliotis J; Lykoudis EG; Zografos GC; Roukos DH
Future Oncol; 2017 Jan; 13(2):113-116. PubMed ID: 27581662
[No Abstract] [Full Text] [Related]
2. Delineating cancer evolution with single-cell sequencing.
Navin NE
Sci Transl Med; 2015 Jul; 7(296):296fs29. PubMed ID: 26180099
[TBL] [Abstract][Full Text] [Related]
3. Resolving genetic heterogeneity in cancer.
Turajlic S; Sottoriva A; Graham T; Swanton C
Nat Rev Genet; 2019 Jul; 20(7):404-416. PubMed ID: 30918367
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer intratumor genetic heterogeneity: causes and implications.
Ng CK; Pemberton HN; Reis-Filho JS
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1021-32. PubMed ID: 23030222
[TBL] [Abstract][Full Text] [Related]
5. Assessing HER2 status in breast cancer through next-generation sequencing of circulating tumor cells.
Di Cosimo S; Silvestri M; De Marco C; Reduzzi C; Folli S; De Santis MC; Cappelletti V
Int J Biol Markers; 2024 Jun; 39(2):184-185. PubMed ID: 38646675
[No Abstract] [Full Text] [Related]
6. Intratumor Heterogeneity in Breast Cancer.
Beca F; Polyak K
Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535
[TBL] [Abstract][Full Text] [Related]
7. Tumoral heterogeneity of breast cancer.
Roulot A; Héquet D; Guinebretière JM; Vincent-Salomon A; Lerebours F; Dubot C; Rouzier R
Ann Biol Clin (Paris); 2016 Dec; 74(6):653-660. PubMed ID: 27848916
[TBL] [Abstract][Full Text] [Related]
8. Molecular heterogeneity in breast cancer: State of the science and implications for patient care.
Ellsworth RE; Blackburn HL; Shriver CD; Soon-Shiong P; Ellsworth DL
Semin Cell Dev Biol; 2017 Apr; 64():65-72. PubMed ID: 27569190
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology.
Ziogas DE; Kyrochristos ID; Roukos DH
Expert Rev Med Devices; 2018 Jan; 15(1):1-3. PubMed ID: 29284319
[No Abstract] [Full Text] [Related]
10. [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].
Gonçalves A; Moretta J; Eisinger F; Bertucci F
Bull Cancer; 2013 Dec; 100(12):1295-310. PubMed ID: 24225763
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing in breast cancer: first take home messages.
Desmedt C; Voet T; Sotiriou C; Campbell PJ
Curr Opin Oncol; 2012 Nov; 24(6):597-604. PubMed ID: 23014189
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing of cancer genomes: lessons learned.
Corrigan AE; Taylor R; Rallis KS
Future Oncol; 2021 Nov; 17(31):4041-4044. PubMed ID: 34431364
[No Abstract] [Full Text] [Related]
13. By the numbers: does circulating tumor cell enumeration have a role in metastatic breast cancer?
Liu MC
J Clin Oncol; 2014 Nov; 32(31):3479-82. PubMed ID: 25245442
[No Abstract] [Full Text] [Related]
14. Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine.
Aleskandarany MA; Vandenberghe ME; Marchiò C; Ellis IO; Sapino A; Rakha EA
Pathobiology; 2018; 85(1-2):23-34. PubMed ID: 29428954
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer intra-tumor heterogeneity.
Martelotto LG; Ng CK; Piscuoglio S; Weigelt B; Reis-Filho JS
Breast Cancer Res; 2014 May; 16(3):210. PubMed ID: 25928070
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour cells: insights into tumour heterogeneity.
Hayes DF; Paoletti C
J Intern Med; 2013 Aug; 274(2):137-43. PubMed ID: 23844916
[TBL] [Abstract][Full Text] [Related]
17. Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches.
Balzerano A; Paccosi E; Proietti-De-Santis L
Cytogenet Genome Res; 2021; 161(6-7):362-371. PubMed ID: 34461614
[TBL] [Abstract][Full Text] [Related]
18. Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges.
Roukos D
Pharmacogenomics J; 2013 Jun; 13(3):205-8. PubMed ID: 23296155
[No Abstract] [Full Text] [Related]
19. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor Cells.
Paoletti C; Hayes DF
Adv Exp Med Biol; 2016; 882():235-58. PubMed ID: 26987538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
